Chief Executive Officer

Chief Financial Officer

JPM26: 2025 a “breakout year” for rare disease biotechs

Alnylam unveils “Alnylam 2030” strategy to fuel growth and patient reach

Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale

ALNY: Ambitious 2030 strategy aims for global TTR leadership and $10B+ annual revenue

Vice President, Target Discovery, Validation, and Human Genetics

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, seeking a visionary scientific leader to serve as Vice President of Target Discovery, Validation, and Human Genetics. This role involves leading teams to identify and validate novel therapeutic targets, integrating human genetics with biological expertise, and ensuring the organization excels in genetically informed drug discovery.

Vice President, Target Discovery, Validation, And Human Genetics in united states (1000+)

Vice President, Target Discovery, Validation, and Human Genetics